Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.99 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.87 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | INSR | P06213 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.87 |
| ▸ | SRC | P12931 | 1/20 | 0.87 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.87 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.87 |
| ▸ | CDK2 | P24941 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL31732815 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL571898 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29251597 | 0.95 | ABCB11 (0.91) | ABCB11EGFRERBB2MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | claimed |
| EP-3674302-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORP (US) | 2023-03-01 | — | — | EP | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | disclosed |
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230285405-A1 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | THE UNIVERSITY OF CHICAGO (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230136878-A1 | CARDIOMYOCYTE PURIFICATION METHOD | Orizuru Therapeutics, Inc. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230131334-A1 | COMPANION DIAGNOSTIC BIOMARKERS OF EGFR INHIBITOR | SYNTEKABIO, INC. (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4123015-A1 | CARDIOMYOCYTE PURIFICATION METHOD | Orizuru Therapeutics, Inc. (JP) | 2023-01-25 | — | — | EP | disclosed |
| US-20220195408-A1 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285405-A1 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | CTRB1, CMA1, MAN2B1 | EGFR 696/4885ERBB2 150/4885ABCB11 204/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | EGFR 5/4885ERBB2 275/4885ABCB11 154/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | EGFR 3552/4885ERBB2 2225/4885ABCB11 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.